{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:11:01Z","timestamp":1787314261375,"version":"build-2736575974"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are limited data on the role of proactive therapeutic drug monitoring (TDM) of ustekinumab (UST) in patients with inflammatory bowel disease (IBD). This study investigated the efficacy and safety of proactive TDM in IBD patients treated with subcutaneous (sc) UST.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective single-center cohort study. Consecutive patients with IBD who received maintenance subcutaneous (sc) UST therapy and underwent TDM from January 2017 to February 2023 were eligible for inclusion. Patients were followed through May 2024 or until drug discontinuation or an IBD-related surgery. Patients underwent either at least one proactive TDM or reactive TDM only. Survival analysis was performed to evaluate drug persistence, defined as no need for drug discontinuation due to loss of response, serious adverse event (SAE) or an IBD-related surgery, and IBD-related hospitalizations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study population consisted of 83 patients (proactive TDM, n\u2005=\u200546) of whom 67 (81%) had Crohn\u2019s disease. Patients who had at least one proactive TDM had higher drug persistence (Log-rank P\u2005&amp;lt;\u2005.001) and less IBD-related hospitalization (Log-rank P\u2005=\u2005.012) compared to patients undergoing only reactive TDM. In multivariable COX proportional hazard regression analysis, at least one proactive TDM was associated with increased drug persistence (hazard ratio [HR]: 5; 95% confidence interval [95% CI], 2-10; P\u2005&amp;lt;\u2005.001) and decreased IBD-related hospitalization (HR: 0.24; 95% CI, 0.07-0.83; P\u2005=\u2005.024). There was no SAE reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This retrospective study showed that proactive TDM is associated with increased drug persistence and decreased IBD-related hospitalization in IBD patients treated with sc UST.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izae231","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T20:24:51Z","timestamp":1726086291000},"page":"1806-1810","source":"Crossref","is-referenced-by-count":17,"title":["Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"31","author":[{"given":"Rachel","family":"Porth","sequence":"first","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Deyhim","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Geeganage","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenden","family":"Smith","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Zullow","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren G","family":"Rabinowitz","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie B","family":"Grossberg","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S","family":"Cheifetz","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1497-0254","authenticated-orcid":false,"given":"Konstantinos","family":"Papamichael","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,26]]},"reference":[{"issue":"2","key":"2025070803364949700_CIT0001","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","article-title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives","volume":"7","author":"Papamichael","year":"2022","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"6","key":"2025070803364949700_CIT0002","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more cost-effective than dose intensification in patients with Crohn\u2019s disease who lose response to anti-TNF treatment: a randomised, controlled trial","volume":"63","author":"Steenholdt","year":"2014","journal-title":"Gut."},{"issue":"12","key":"2025070803364949700_CIT0003","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/apt.17313","article-title":"Meta-analysis: the efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease","volume":"57","author":"Sethi","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"issue":"Suppl","key":"2025070803364949700_CIT0004","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.gastro.2022.06.052","article-title":"Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: a systematic review and meta-analysis","volume":"163","author":"Nguyen","year":"2022","journal-title":"Gastroenterology."},{"issue":"10","key":"2025070803364949700_CIT0005","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cgh.2017.03.031","article-title":"Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab","volume":"15","author":"Papamichael","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"8","key":"2025070803364949700_CIT0006","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/ecco-jcc\/jjz018","article-title":"Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease","volume":"13","author":"Papamichael","year":"2019","journal-title":"J Crohns Colitis."},{"issue":"7","key":"2025070803364949700_CIT0007","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1007\/s10620-021-07173-1","article-title":"Ustekinumab therapeutic drug monitoring-impact on clinical practice: a multicenter cross-sectional observational trial","volume":"67","author":"Afif","year":"2022","journal-title":"Dig Dis Sci."},{"key":"2025070803364949700_CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.03.039","article-title":"Risankizumab concentration but not IL-22 levels are associated with clinical and biochemical remission in patients with Crohn\u2019s disease","volume":"S1542-3565(24)00402-6","author":"Roblin","year":"2024","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025070803364949700_CIT0009","doi-asserted-by":"publisher","first-page":"izae140","DOI":"10.1093\/ibd\/izae140","article-title":"Proactive therapeutic drug monitoring is associated with increased drug persistence in patients with inflammatory bowel disease treated with intravenous vedolizumab","author":"Porth","year":"2024","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2025070803364949700_CIT0010","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/jpn3.12132","article-title":"Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease","volume":"78","author":"Patrick Rowland","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"2","key":"2025070803364949700_CIT0011","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/jcag\/gwaa003","article-title":"Comparison of serum concentrations of ustekinumab obtained by three commercial assays in patients with Crohn\u2019s disease","volume":"4","author":"Verdon","year":"2020","journal-title":"J Can Assoc Gastroenterol."},{"issue":"11","key":"2025070803364949700_CIT0012","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1093\/ibd\/izab357","article-title":"Long-term real-world effectiveness and safety of ustekinumab in Crohn\u2019s disease patients: the SUSTAIN study","volume":"28","author":"Chaparro","year":"2022","journal-title":"Inflamm Bowel Dis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae231\/59361129\/izae231.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/7\/1806\/59361129\/izae231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/7\/1806\/59361129\/izae231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T03:36:52Z","timestamp":1751945812000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/7\/1806\/7778240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,26]]},"references-count":12,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,9,26]]},"published-print":{"date-parts":[[2025,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae231","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2024,9,26]]}}}